Search Results - TherapeuticArea+%3e+Oncology

560 Results

Sort By:

Characterization of novel pan anti-HLA antibodies that block LILR inhibitory receptors and activate anti-tumor immunity

Cancer immunotherapy has transformed treatment for some patients, but many tumors still do not respond well to current options, including checkpoint inhibitors. Researchers at NIAID’s Laboratory of Immune System Biology (LISB) have developed new antibodies designed to help the immune system fight tumors. These lab-made antibodies, called pan-anti-HLA...

Published: 7/16/2026 | Updated: 7/16/2026 | Inventor(s): David Margulies, Abir Panda, Ethan Shevach, Kannan Natarajan, Patricia Korty

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought, TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease

MC38 B2m KO Cell Line

Summary: The National Cancer Institute (NCI) seeks licensees for a CRISPR/Cas9-engineered MC38 B2m knockout murine colon cancer cell line that models tumor resistance to PD-1/PD-L1 checkpoint blockade caused by loss of MHC-I antigen presentation. This research tool provides an opportunity to study checkpoint-refractory tumors and evaluate alternative...

Published: 7/14/2026 | Updated: 7/14/2026 | Inventor(s): Jeffrey Schlom, Duane Hamilton

Keywords(s):

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials

Quantitative Particle Identification (QPID) Digital Autoradiography System

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities. Description of Technology: Autoradiography is a photographic process that exposes a medium, sensitive to radiation, to a sample...

Published: 7/9/2026 | Updated: 7/8/2026 | Inventor(s): Stephen Adler

Keywords(s):

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Radiology, Application > Non-Medical Devices

Interferon Gamma for Retinal Fluid Absorption Restoration

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of Interferon gamma as a therapeutic agent to restore retinal fluid absorption. This technology includes the use of Interferon gamma to restore fluid absorption in retinal pigment epithelial (RPE) cells, specifically targeting the adverse effects...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Charlotte Reme, Sheldon Miller, Arvydas Maminishkis

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology

AI Based Workflow for Single Cell Analysis

The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations. This technology includes SCassist, an innovative...

Published: 6/18/2026 | Updated: 6/16/2026 | Inventor(s): Rachel Caspi, Vijayaraj Nagarajan

Keywords(s):

Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy

Summary: Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees...

Published: 5/14/2026 | Updated: 5/14/2026 | Inventor(s): Steven Rosenberg, Sanghyun (Peter) Kim

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 4/30/2026 | Updated: 4/30/2026 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen. This technology encompasses a DNA methylation–based diagnostic platform designed to improve the accuracy and consistency of cancer classification,...

Published: 4/23/2026 | Updated: 4/10/2026 | Inventor(s): Kenneth Aldape, Ziedulla Abdullaev, Rustamzhon Turakulov, Stefania Pittaluga, Mark Raffeld, Elaine Jaffe, Omkar Singh, Antonios Papanicolau-Sengos

Keywords(s):

Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia

Summary: The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. Description of Technology: Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis...

Published: 4/10/2026 | Updated: 4/10/2026 | Inventor(s): Vid Leko, Aidan Pursley, Kenichi Hanada, Zhiya Yu, Catherine Ade, James Yang

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Humanized 40H3 Antibody

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Updated: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

1 2 3 4 5 6 7 8 9 10 ...